Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third party review

This article was originally published in The Gray Sheet

Executive Summary

"We will soon be notifying Congress that we believe we have met" one of the sunset criteria in the latest expansion of the third-party program, FDA's Eric Rechen reports June 15 during the AdvaMed workshop. The sunset provision triggers the termination of authority for the program in five-years unless Congress reauthorizes it. GAO is required by law to conduct several studies to help Congress evaluate the program prior to the expiration of the third party program, however, Rechen notes. By the end of this year, the Office of Compliance will have audited "all of the most active third parties," Rechen also adds

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel